Recent Investments/Transactions

EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards.

At the top of the Nasdaq Composite’s chart is Black Titan Corp. with a massive increase of nearly 300%. In early morning pre-trading for Friday, though, the stock dipped 28%.

HONG KONG, July 2, 2025 /PRNewswire/ -- FiEE, Inc. (NASDAQ:MINM) ("FiEE" or the "Company"), a technology company integrating IoT, connectivity and AI to redefine brand management solutions in the digital era, is pleased to announce that on June 30, 2025, it entered into an asset purchase agreement with Suzhou Yixuntong Network Technology Co., Ltd. ("Yixuntong") to acquire intellectual property and fixed assets for a total purchase price of USD1,400,000 (the "Acquisition").

Company resumed trading under its existing symbol "MINM" HONG KONG, June 2, 2025 /PRNewswire/ -- FiEE, Inc. (NASDAQ:MINM) ("FiEE, Inc." or the "Company"), a technology company integrating IoT, connectivity and AI to redefine brand management solutions in the digital era, commenced the trading of its common stock on Monday, June 2, 2025 on the Nasdaq Capital Market under the ticker symbol "MINM".

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.)

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”).

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025

David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced that the Company entered into a securities purchase agreement (“Agreement”) with investor David Lazar (“Lazar”)..